Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | UGCG | Q16739 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17137021 | 1.00 | ESR1 (0.53) | ESR1EPHX2CNR2NPC1RAB9A | |
| SCHEMBL17136773 | 0.85 | JAK3 (0.53) | NPC1RAB9A | |
| SCHEMBL30668358 | 0.85 | JAK3 (0.53) | NPC1RAB9A | |
| SCHEMBL17136714 | 0.82 | CNR2 (0.47) | CNR2NPC1RAB9AMAPTUGCG | |
| SCHEMBL30668359 | 0.82 | CNR2 (0.47) | CNR2NPC1RAB9AMAPTUGCG | |
| SCHEMBL30668308 | 0.81 | SCN9A (0.42) | ESR1EPHX2 | |
| SCHEMBL17136910 | 0.81 | SCN9A (0.42) | ESR1EPHX2 | |
| SCHEMBL17136952 | 0.80 | CNR2 (0.43) | CNR2MAPTUGCGABL1TRPV1 | |
| SCHEMBL17136788 | 0.80 | ABL1 (0.45) | CNR2MAPTUGCGABL1TRPV1 | |
| SCHEMBL17136963 | 0.80 | CNR2 (0.50) | CNR2MAPTUGCGABL1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | ESR1 2332/4885EPHX2 3631/4885CNR2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.